Drugs / 68Ga-HX01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05490849 | Oct 2021 → Jun 2023 | cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06416774 | Dec 2022 → Jul 2023 | cancer | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-HX01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06416774 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-HX01 PET imaging in the diagnosis and staging of malignant tumors” NCT05490849 ↗ |
| Route | Intravenous | “after a single intravenous administration” NCT06416774 ↗ |